Toggle Menu

Press Room

Papillary Kidney Cancer Clinical Trials

02/03/2012

This page is dedicated to bringing you the most current information about clinical trials for papillary kidney cancer. In a small number of cases, papillary renal cell carcinoma is hereditary. This disease accounts for a small percentage of all cases of kidney cancer.

Dilemma of the Small Renal Mass

02/03/2012

2012 Genitourinary Cancers Symposium Daily News: By: Sima Porten, MD, MPH, and Maxwell V. Meng, MD The past decade has seen significant advances in the treatment of patients with renal cell carcinoma, with the widespread adoption of minimally invasive surgical techniques and the approval of several targeted systemic agents for metastatic disease.

GU ASCO: The Role of Cytoreductive Nephrectomy

02/03/2012

By: Thomas Powles, MD The introduction of agents targeting angiogenesis and the mTOR pathway have substantially improved the outcome of metastatic renal cell carcinoma (mRCC). Cytoreductive nephrectomy remains the standard of care in the era of targeted therapy. This is based on data from two randomized trials comparing nephrectomy and immune therapy with immune therapy alone.

AGS-003 with sunitinib and overall survival

02/02/2012

AGS-003 in Combination With Sunitinib Shows Statistically Significant Correlation of Immune System Response to Overall Survival

Kidney Papillary Carcinoma

02/02/2012

Kidney clear cell carcinoma is the most common type of kidney cancer, representing approximately 92 percent of such cases. Papillary carcinoma accounts for about 8 percent.

2012 GU ASCO "Daily News"

02/01/2012

The Kidney Cancer Association is podcasting live from the 2012 Genitourinary Cancers Symposium, in San Francisco. For the latest information from this event,be sure to read the "Daily News" online.

Quality of life during dendritic cell vaccination

02/01/2012

The data indicate that dendritic cells (DCs) vaccination, which is a personalised treatment modality, maintains quality of life (QoL) and thus represents an attractive nontoxic treatment option for patients with metastatic renal cell carcinoma (RCC).

Small Renal Oncocytomas

02/01/2012

To evaluate characteristic imaging findings of tumor attenuation in multiphase computed tomography (CT) between renal oncocytomas and clear-cell renal cell carcinoma (ccRCC) of small tumor size (

Familial renal cancer as an indicator

02/01/2012

Hereditary Leiomyomatosis and Renal Cell Carcinoma (HLRCC) is a hereditary condition which typically presents with cutaneous and uterine leiomyomata. Papillary type II renal cell carcinoma and other less common histologic subtypes of renal cancer have been reported in HLRCC.

Thermal ablation of renal cell carcinoma

02/01/2012

The incidence of renal cell carcinoma (RCC) is increasing. With the increasing emphasis on minimally invasive nephron-sparing surgery, thermal ablation is playing a larger role in the management of patients with this disease.

Previous  |  1  |  2  |  3  |  4  |  5  |  6  |  7  |  8  |  9  |  10  |  11  |  12  |  13  |  14  |  15  |  16  |  17  |  18  |  19  |  20  |  21  |  22  |  23  |  24  |  25  |  26  |  27  |  28  |  29  |  30  |  31  |  32  |  33  |  34  |  35  |  36  |  37  |  38  |  39  |  40  |  41  |  42  |  43  |  44  |  45  |  46  |  47  |  48  |  49  |  50  |  51  |  52  |  53  |  54  |  55  |  56  |  57  |  58  |  59  |  60  |  61  |  62  |  63  |  64  |  65  |  66  |  67  |  68  |  69  |  70  |  71  |  72  |  73  |  74  |  75  |  76  |  77  |  78  |  79  |  80  |  81  |  82  |  83  |  84  |  85  |  86  |  87  |  88  |  89  |  90  |  91  |  92  |  93  |  94  |  95  |  96  |  97  |  98  |  99  |  100  |  101  |  102  |  103  |  104  |  105  |  106  |  107  |  108  |  109  |  110  |  111  |  112  |  113  |  114  |  115  |  116  |  117  |  118  |  119  |  120  |  121  |  122  |  123  |  124  |  125  |  126  |  127  |  128  |  129  |  130  |  131  |  132  |  133  |  134  |  135  |  136  |  137  |  138  |  139  |  140  |  141  |  142  |  143  |  144  |  145  |  146  |  147  |  148  |  149  |  150  |  151  |  152  |  153  |  154  |  155  |  156  |  157  |  158  |  159  |  160  |  161  |  162  |  163  |  164  |  165  |  166  |  167  |  168  |  169  |  170  |  171  |  172  |  173  |  174  |  175  |  176  |  177  |  178  |  179  |  180  |  181  |  182  |  183  |  184  |  185  |  186  |  187  |  188  |  189  |  190  |  191  |  192  |  193  |  194  |  195  |  196  |  197  |  198  |  199  |  200  |  201  |  202  |  203  |  204  |  205  |  206  |  207  |  208  |  209  |  210  |  211  |  212  |  213  |  214  |  215  |  216  |  217  |  218  |  219  |  220  |  221  |  222  |  223  |  224  |  225  |  226  |  227  |  228  |  229  |  230  |  231  |  232  |  233  |  234  |  235  |  236  |  237  |  238  |  239  |  240  |  241  |  242  |  243  |  244  |  245  |  246  |  247  |  248  |  249  |  250  |  251  |  252  |  253  |  254  |  255  |  256  |  257  |  258  |  259  |  260  |  261  |  262  |  263  |  264  |  265  |  266  |  267  |  268  |  269  |  270  |  271  |  272  |  273  |  274  |  275  |  276  |  277  |  278  |  279  |  280  |  281  |  282  |  283  |  284  |  285  |  286  |  287  |  288  |  289  |  290  |  291  |  292  |  293  |  294  |  295  |  296  |  297  |  298  |  299  |  300  |  301  |  302  |  303  |  304  |  305  |  306  |  307  |  308  |  309  |  310  |  311  |  312  |  313  |  314  |  315  |  316  |  317  |  318  |  319  |  320  |  321  |  322  |  323  |  324  |  325  |  326  |  327  |  328  |  329  |  330  |  331  |  332  |  333  |  334  |  335  |  336  |  337  |  338  |  339  |  340  |  341  |  342  |  343  |  344  |  345  |  346  |  347  |  348  |  349  |  350  |  351  |  352  |  353  |  354  |  355  |  356  |  357  |  358  |  359  |  360  |  361  |  362  |  363  |  364  |  Next
NeonCRM by Neon One